Literature DB >> 26634943

Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary.

Susan D Mathias1, Steven R Feldman2, Ross D Crosby1,3,4, Hilary H Colwell1, Kelly McQuarrie5, Chenglong Han5.   

Abstract

BACKGROUND: Collecting reliable and valid symptom information from patients is critical for assessing psoriasis severity in clinical research.
OBJECTIVE: To evaluate measurement properties of a new patient-reported outcome (PRO), the Psoriasis Symptoms and Signs Diary (PSSD).
METHODS: One hundred six US patients with moderate-to-severe plaque psoriasis completed two versions of the PSSD [a 24-hour recall (PSSD-24h) and 7-day recall (PSSD-7d)] using a 0-10 numerical rating scale. Reliability (test-retest and internal consistency), validity (convergent, divergent and known-groups), responsiveness, and version equivalence were evaluated. Minimally important difference was estimated.
RESULTS: Based on exploratory factor analysis and clinical input, symptom, sign, and total severity scores were established. Internal consistency (Cronbach's alpha ≥ 0.944) and test-retest reliability (intraclass correlation coefficients ≥ 0.824) were acceptable. Correlations with Dermatology Life Quality Index (DLQI) (0.489 to 0.644) indicated convergent validity, while low correlations (< 0.30) with several Short Form (SF)-36 scales indicated divergent validity. PSSD scores differed when patients were categorized by Body Surface Area, DLQI, and Psoriasis Area Severity Index scores. PSSD-24h and PSSD-7d versions were equivalent (Pearson correlations ≥ 0.953). LIMITATIONS: PSSD responsiveness should be evaluated in patients receiving treatment.
CONCLUSION: The PSSD is reliable and valid in measuring symptoms/signs of patients with moderate-to-severe plaque psoriasis.

Entities:  

Keywords:  Psoriasis; assessment tool; minimal important difference; questionnaire; reliability; validity

Mesh:

Year:  2015        PMID: 26634943     DOI: 10.3109/09546634.2015.1114567

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  2 in total

1.  Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.

Authors:  K A Papp; A Blauvelt; A B Kimball; C Han; B Randazzo; Y Wasfi; Y-K Shen; S Li; C E M Griffiths
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-04-10       Impact factor: 6.166

2.  Individual Burden of Psoriasis (I-BOP): Building and Validation of a New Scoring Tool for Patients with Psoriasis.

Authors:  Charles Taieb; François Maccari; Khaled Ezzedine; Anne Claire Fougerousse; Roberte Aubert; Jean-Benoît Monfort; Ziad Reguiaï; Jason Shourick
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-05-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.